
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

BioSpectrum Ranking Survey: Rank 1: Serum Institute of India

15 September 2016 | Features | By BioSpectrum Bureau

BioSpectrum Ranking Survey: Rank 1: Serum Institute of India



Serum Institute of India
Name: Dr Cyrus Poonawalla
Designation: CMD
Revenue: Rs 4,153 crore

Serum Institute is the world's largest vaccine manufacturer by number of doses produced and sold globally - the number of doses account to more than 1.3 billion.
It supplies vaccines to more than 140 countries. According to the company, 65 percent of all the children in the world receive at least one vaccine produced by Serum Institute.

For the FY2015-16, the company achieved a revenue of Rs 4,153 crore.
Delivering world class, high quality and affordable vaccines to the world, the company has collaborated with global health organizations including WHO, NIH, PATH, NVI/RIVM and CBER/USFDA, developing vaccines against Meningococcal A, H1N1 Influenza, Rotavirus and other diseases.

In December 2015, the company announced its interest in entering the Russian market through a joint venture (JV) with the Russian government-owned vaccine maker, National Immunobiological Company (NIC).

Through this JV, Serum aims to increase its sales up to $60-80 million by FY2017-18.
Prior to this, in June 2015, the Poonawalla Group in a move decided to sell 20 percent of its stake in Serum Institute of India (SIL).

September 2015 saw Serum buying exclusive rights from US-based Visterra, to sell its monoclonal antibody (mAb) in treating dengue in India. The transaction was priced at $39 million.